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Background: Lafora disease is characterized by 
abnormal, hyperphosphorylated glycogen. 
Results: 20% of the total phosphate is present as a 
C6 phosphomonester of glucose residues; this 
proportion is unchanged in glycogen from mouse 
models of Lafora disease. 
Conclusion:  C6 phosphate is not the dominant 
phosphomonoester.  
Significance: C2, C3 or C6 phosphate could all 
contribute to aberrant glycogen structure. 
 
Glycogen is a branched polymer of glucose that 
acts as an energy reserve in many cell types.  
Glycogen contains trace amounts of covalent 
phosphate, in the range of one phosphate per 
500-2000 glucose residues, depending on the 
source.  The function, if any, is unknown but in 
at least one genetic disease, the progressive 
myooclonic epilepsy Lafora disease, excessive 
phosphorylation of glycogen has been implicated 
in the pathology by disturbing glycogen 
structure.  Some 90% of Lafora cases are 
attributed to mutations of the EPM2A or 
EPM2B genes and mice with either gene 
disrupted accumulate hyperphosphorylated 
glycogen.  It is therefore of importance to 
understand the chemistry of glycogen 
phosphorylation.  Rabbit skeletal muscle 
glycogen contained covalent phosphate as 
monoesters of C2, C3 and C6 carbons of glucose 
residues based on analyses of phospho-
oligosaccharides by NMR.  Furthermore, using a 
sensitive assay for glucose-6-P in hydrolysates of 
glycogen coupled with measurement of total 
phosphate, we determined the proportion of C6 
phosphorylation in rabbit muscle glycogen to be 
~20%.  C6 phosphorylation also accounted for 
~20% of the covalent phosphate in wild type 
mouse muscle glycogen.  Glycogen 
phosphorylation in Epm2a-/- and Epm2b-/- mice 
was increased eight- and four-fold compared to 
wild type mice but the proportion of C6 
phosphorylation remained unchanged at ~20%.  
Therefore, our results suggest that C2, C3 
and/or C6 phosphate could all contribute to 
abnormal glycogen structure or to Lafora 
disease. 
 
 
Glycogen, the widely distributed carbohydrate 
store, is a polymer of glucose formed of α-1,4-
glycosidic linkages with branch points introduced 
by α-1,6-glycosidic linkages, on average one per 
twelve glucose residues (1).  A common model for 
glycogen structure envisages successive layers of 
glucose chains, average length 13 residues, up to a 
maximum of 12 tiers, so that a fully formed 
molecule would contain ~55,000 glucose residues 
(2-4).  Glycogen also contains trace amounts of 
covalent phosphate (5-7) that, from more recent 
analyses, normally occurs in the range of one 
phosphate per 500-2000 glucose residues 
depending on the source of the glycogen (1).  The 
early work from Whelan and colleagues (6,7) had 
suggested that the phosphate was present as a C6 
phosphomonoester or a C1-C6 phosphodiester, the 
latter introduced by a putative glucose-1-
phosphotransferase enzyme.   
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The phosphorylation of glycogen has attracted 
recent attention because of its implication in Lafora 
disease, a juvenile-onset genetic disease 
characterized by progressive myoclonic epilepsy 
and a gradual deterioration of neurological function 
culminating in death usually within ten years of 
diagnosis (8-12).  A characteristic of the disease is 
the occurrence of deposits, called Lafora bodies, in 
neurons, muscle, heart, skin and other tissues.  
Lafora bodies contain a poorly branched glycogen-
like substance, termed polyglucosan, which is 
hyper-phosphorylated.  Some 90% of the instances 
of Lafora disease can be traced to mutations in 
either of two genes, EPM2A and EPM2B/NHLRC1 
which respectively encode proteins called laforin 
(13,14) and malin (15).  Disruption of either gene in 
mice results in the formation of Lafora bodies and 
reproduces a number of the neurological defects of 
the human disease (16-21).  The connection with 
glycogen phosphorylation came with the 
recognition that laforin, by sequence a member of 
the atypical dual specificity protein phosphatase 
family (22), was able to dephosphorylate 
amylopectin (23,24) and glycogen (24) in vitro.  
Furthermore, glycogen from laforin knockout mice 
had elevated levels of phosphorylation (24) that 
could be linked to abnormalities in glycogen 
structure conducive to the generation of Lafora 
bodies (25).   
 
The recent interest in glycogen phosphorylation led 
to renewed investigation of the chemical linkage 
and the origin of the phosphate in glycogen.  
Tagliabracci et al. (26) purified phospho-
oligosaccharides from rabbit muscle glycogen by 
anion exchange chromatography and, from NMR 
analysis, identified the presence of both C2 and C3 
phosphomonoesters.  A subsequent study by 
Nitschke et al. (27) confirmed the presence of C2 
and C3 monoesters and additionally presented 
evidence for C6 phosphomonoester by NMR 
analyses.  Neither study found evidence for the C1-
C6 phosphodiester proposed by Lomako et al. (6).  
In addition, Nitschke et al. (27) utilized an 
enzymatic assay to measure glucose-6-P in 
hydrosylates of glycogen in the presence of the 
resulting high glucose background.  Using this 
protocol, they detected increased C6 
phosphorylation of glycogen in laforin and malin 
knockout mice but did not report what proportion it 
was of the total covalent phosphate.  They 
concluded that elevated C6 phosphorylation 
interfered with branching, resulting in the 
malformed glycogen responsible for the 
neurodegeneration of Lafora disease. 
 
In the present study, we undertook further analysis 
of the phosphorylation of muscle glycogen.  We 
confirmed the presence of C6 phosphate by NMR 
and by enzymatic glucose-6-P determination in 
mouse and rabbit skeletal muscle glycogen.  In wild 
type mouse muscle glycogen, C6 phosphorylation 
accounted for ~20% of the total phosphate and, as 
the total glycogen phosphate was elevated 4 to 8-
fold in laforin or malin knockout mice, the 
proportion of C6 phosphate remained constant at 
~20%.  Therefore, from our results we cannot 
determine which, if any, phosphorylation is most 
important for causing abnormal glycogen structure 
and hence Lafora disease.  
 
EXPERIMENTAL PROCEDURES 
 
Animals.   
Epm2a-/- mice in a mixed C57BL/6 X 129Svj 
background (16) originated with Dr. Delgado-
Escueta and were backcrossed five times with 
C57BL/6 mice.  Heterozygotes from this generation 
were crossed to generate Emp2a-/- and Epm2a+/+ 
mice (28).  Intercrossing of these mice (Epm2a-/- X 
Epm2a-/- and Epm2a+/+ X Epm2a+/+) produced 
the experimental mice used in this study.  Epm2b-/- 
mice were generated as described by DePaoli-
Roach et al. (17).  Briefly, C57BL/6N ES cells 
disrupted for Epm2b were injected into C57BL/6J 
blastocysts that resulted in a male chimeric mouse 
that gave germline transmission after crossing with 
C57BL/6 females.  The resulting Epm2b-/+ mice 
were intercrossed and the resulting progeny used 
for Epm2b-/- X Epm2b-/- and Epm2b+/+ X 
Epm2b+/+ crosses to generate the experimental 
animals.  All mice were maintained in temperature- 
and humidity-controlled conditions with a 12:12 hr 
light-dark cycle at the Indiana University School of 
Medicine Laboratory Animal Resource Center, 
were fed a standard chow (Harlan Teklad global 
diet 2018SX) and allowed food and water ad 
libitum.  New Zealand white rabbits were 
purchased from Harlan and housed temporarily in 
the Indiana University School of Medicine 
Laboratory Animal Resource Center until they were 
sacrificed.  Liver and skeletal muscle were 
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harvested and frozen in liquid nitrogen and the 
majority of the skeletal muscle was used fresh for 
purification of glycogen by Method 1 below.  All 
studies were conducted in accordance with federal 
guidelines and were approved by the Institutional 
Animal Care and Use Committee of Indiana 
University School of Medicine.  
 
Purification of glycogen 
Rabbit muscle glycogen was purified by either of 
two procedures, one involving treatment of muscle 
extracts with 10% TCA (w/v) at 4oC to remove 
protein prior to precipitation with ethanol (Method 
1) and the other involving direct KOH digestion of 
muscle (Method 2).  Two male New Zealand white 
rabbits, ~ 2 kg each, were sacrificed by lethal 
injection with pentobarbital (150mg/kg body 
weight) followed by exsanguination. Back and hind 
limb muscles were removed, ~ 75% of the 
harvested muscle was placed immediately under ice 
and used for glycogen purification by Method 1.  
The remaining tissue was flash frozen in liquid N2 
and stored at -80oC for glycogen purification by 
Method 2. 
 
TCA Method.  Freshly harvested rabbit skeletal 
muscle, ~1.45 kg, was cut into small pieces and 
homogenized with three volumes of 4 mM EDTA 
in a large Waring blender, 60 sec  at low speed and 
30 sec at high speed. All procedures, 
homogenizations, centrifugations and other steps 
were conducted at 4oC. The homogenate was 
centrifuged for 45 min at 7,000 x g. The 
supernatant was then passed through two layers of 
Miracloth to remove floating fat.  The recovered 
supernatant (2.8 L) was transferred to a 4 L glass 
beaker placed in an ice bath and 100% (w/v) TCA 
was slowly added under constant stirring to a final 
concentration of 10% TCA. The suspension was 
then centrifuged for 30 min at 7,000 x g, the 
supernatant (2.7 L) transferred to a 4 L glass beaker 
placed in a salt-ice bath and glycogen was 
precipitated by slowly adding 1 volume of -80oC 
100% ethanol. After stirring in the salt-ice bath for 
an additional 20 min, the sample was centrifuged at 
7,000 x g for 60 min, the supernatant was decanted 
and the precipitate redissolved in water using a 
motor driven pestle of a Dounce homogenizer. The 
solution (80 ml) was transferred to a glass Corex 
tube and lipids and other nonpolar contaminants 
were extracted with an equal volume of a 3:1 
chloroform:octanol solution by vigorous mixing 
followed by centrifugation at 6,000 x g for 10 min.  
The aqueous layer was collected and re-extracted 
with an equal volume of 3:1 chloroform:octanol. 
Ten ml of water was added to the organic phase of 
the first extraction, mixed and centrifuged. The 
process was repeated once more and all aqueous 
phases were combined, 90 ml total. Glycogen was 
then precipitated from the aqueous phase by slow 
addition under stirring of an equal volume of -20oC 
100% ethanol and the suspension was kept 
overnight at -20oC. The precipitated glycogen was 
collected by centrifugation, 7,000 x g for 30 min, 
the pellet was redissolved with 45 ml of 1% SDS 
and then subjected to ultracentrifugation in a Ti45 
rotor for 3 hr at 196,000 x g at 4oC. After 
ultracentrifugation the supernatant was decanted 
and 30 ml of water was added to the translucent 
glycogen pellet which was redissolved by rocking 
on a nutator overnight at 4oC. The solution was 
then placed on ice for one hr to precipitate any 
remaining SDS, which was removed by 
centrifugation at 12,000 x g for 20 min. The 
glycogen in the supernatant (45 ml) was 
precipitated with two volumes of -20oC 100% 
ethanol and kept at -20oC for 2.5 hr followed by 
centrifugation at 15,300 x g for 30 min. The 
precipitated glycogen was washed with -20oC 
100% ethanol, centrifuged at 15,300 x g and then 
dissolved in 30 ml of water. The glycogen solution 
was dialyzed using Spectra/Por (Spectrum) 16 mm 
diameter, 12-14,000 MW cutoff dialysis tubing at 
4oC against 4L of water, which was changed after 
4.5 hr and dialysis continued overnight. The 
dialyzed glycogen solution was centrifuged at 
23,000 x g for 20 min to remove insoluble material. 
Glycogen in the supernatant (53 ml) was then 
precipitated with two volumes of -20oC 100% 
ethanol with stirring and then kept at -20oC for 2 hr. 
After centrifugation at 23,000 x g for 20 min, the 
precipitated glycogen was washed with -20oC 
100% ethanol and re-centrifuged.  The pellet was 
kept at room temperature to evaporate all residual 
ethanol. After the glycogen was completely dried, it 
was pulverized using a ceramic mortar and pestle. 
From the 1.45 kg of muscle 4.0 g of glycogen was 
recovered and kept at -20oC until use. 
 
KOH Method.  Flash frozen rabbit skeletal muscle 
(~105 g) stored at -80oC was rapidly broken into 
small pieces and added to 10-volumes of boiling 
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30% (w/v) KOH and maintained in a 100oC water 
bath for 1 hr with mixing about every 10-15 min. 
The digested tissue was then placed on ice to cool 
and centrifuged at 10,000 x g for 10 min. All 
centrifugations were done at 4oC. The supernatant, 
1 L, was filtered through 2 layers of Miracloth to 
remove floating fat, transferred to a 4 L glass 
beaker placed in a salt-ice bath and glycogen was 
precipitated by slow addition of two volumes of -
80oC 100% ethanol with constant stirring in the 
presence of 10 mM LiCl and 0.02% Na2SO4 to aid 
precipitation. After an additional 5-10 min stirring, 
the suspension was placed overnight at -20 oC.  All 
subsequent ethanol precipitations included 6 mM 
LiCl. The precipitated glycogen was collected by 
centrifugation, 7,000 x g for 45 min, the pellet was 
redissolved in 30 ml water and centrifuged at 
10,000 x g for 25 min to remove insoluble material. 
The supernatant (36 ml) was precipitated by adding 
two volumes of -20oC 100% ethanol with the 
addition of LiCl and kept at -20oC for 2 hr. The 
sample was then heated in a boiling water bath for 
3 min, which causes glycogen flocculation, then 
cooled on ice followed by centrifugation 10,000 x g 
for 30 min.  The pellet was redissolved in 20 ml of 
water and 13 ml of the solution was added to each 
of two glass Corex tubes.  Ten volumes of 4:1 
methanol:chloroform solution was added to each 
tube, vigorously mixed and incubated at 80oC for 5 
min. The tubes were then cooled on ice and 
centrifuged at 5,500 x g for 30 min to pellet the 
glycogen. The pellets were dried in a Speed Vac for 
10 min to remove residual solvents, redissolved 
with ~25 ml of water, heated to aid solubilization 
and centrifuged at 10,000 x g for 25 min to remove 
insoluble material. The supernatant was 
precipitated again with two volumes 100% ethanol 
and kept at -20oC overnight. After heating for 2 min 
in a boiling water bath and cooling on ice, the 
sample was centrifuged at 15,000 x g for 30 min. 
The glycogen pellet was dried in a Speed Vac for 5 
min. The pellet was then redissolved with 20 ml of 
water and TCA was added under stirring to a final 
concentration of 10% (w/v) followed by 
centrifugation at 15,000 x g for 30 min. The 
glycogen in the supernatant, 27 ml, was precipitated 
with ethanol and centrifuged at 15,000 x g for 30 
min. The pellet was redissolved in 20 ml of water 
and filtered by passing through one layer of 
Miracloth that had been extensively washed with 
water.  The filtered solution was then transferred to 
dialysis tubing, Spectra/Por, 16 mm diameter, 12-
14,000 MW cutoff, and dialyzed against 4 L of 
water which was changed after 2.5 hr and dialysis 
continued overnight at 4oC. After dialysis the 
glycogen solution (19 ml) was precipitated with 
ethanol and the pellet was dried in a Speed Vac. 
The dried pellet was minced and weighed, yielding 
0.48 g of glycogen.  
 
Glycogen from individual mice was purified from 
~0.5 g samples of hindlimb muscle, flash frozen in 
liquid N2 and stored at -80oC until use, following a 
protocol similar to the KOH method above (24).   
 
Potato amylopectin (Sigma-Aldrich #A8515), to be 
analyzed for phosphate content and as a positive 
control for the presence of glucose-6-P, was also 
subjected to the KOH purification procedure.  Four 
aliquots of ~ 3 mg amylopectin were treated with 
10 volumes of boiling 30% KOH as described for 
the glycogen. After boiling, the samples were 
cooled on ice, precipitated with two volumes of -
20oC 100% ethanol and LiCl and Na2SO4 to final 
concentrations of 10 mM and 0.02% (w/v) 
respectively and kept overnight at -20oC.  The 
samples were then heated in a boiling water bath 
for 2 min, cooled on ice and centrifuged at 15,000 x 
g for 20 min at 4oC. The pellets were redissolved in 
300 µl of water. The precipitation was repeated two 
more times with LiCl at a final concentration of 6 
mM.  After the last precipitation, the amylopectin 
pellets were dried in a Speed Vac for 10 min, 
redissolved in 500 µl H2O and dialyzed in 
Spectra/Por tubing of 10 mm diameter and 12-
14,000 MW cutoff. The samples were dialyzed 
against 4 L of water overnight at 4oC. The 
dialysates were ethanol precipitated again. The 
pellets were dried in a Speed Vac to completely 
remove any residual liquid, weighed, dissolved in 
water at a final concentration of ~ 5 mg/ml and 
stored at -20oC until use. 
 
Glycogen and inorganic phosphate 
determination 
The concentration of purified mouse and rabbit 
skeletal muscle glycogen, and amylopectin, was 
determined as described in Suzuki et al. (29) by the 
method of Bergmeyer (30).  Approximately 50-150 
µg of purified polysaccharide was digested in 50 ml 
0.2 M sodium acetate pH 4.8 containing 0.3 mg/ml 
amyloglucosidase (Aspergillus niger; Sigma-
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Aldrich) at 40oC overnight. The digest was diluted 
2-4 fold with H2O and 10 ml was added to 0.3 ml of 
the glucose assay reaction consisting of 0.3 M 
triethanolamine pH7.6, 4 mM MgCl2, 0.9 mM 
NADP+ and 2 µg/ml glucose-6-P dehydrogenase 
(Roche).  Background absorbance was determined 
at 340 nm. Samples were then incubated with 5 mg 
hexokinase (Roche) at room temperature for 30 min 
and absorbance was measured again. Background 
absorbance was subtracted from sample absorbance 
and glucose equivalents were determined based on 
a molar extinction coefficient for NADPH of 6.22 x 
103. 
 
Polysaccharide phosphate content of mouse or 
rabbit skeletal muscle glycogen and potato 
amylopectin was determined using the sensitive 
Malachite green assay as described previously 
(24,31).  Briefly, triplicate samples of ~200 µg of 
purified polysaccharide were taken, one as a non-
hydrolyzed control for free phosphate 
determination and two for hydrolysis.   Samples 
were hydrolyzed in 40 µl of a 3:1 solution of 60% 
HClO4:10 N H2SO4 at 190oC for 2 hr.  After 
hydrolysis, samples were dissolved in 100 µl of 
water, 400 ml of Malachite green solution (31) 
were added and absorbance at 620 nm was 
determined.  Phosphate content was quantitated 
based on a KH2PO4 standard curve, which was 
linear up to 7 nmol/assay.  No phosphate was 
detected in the non-hydrolyzed controls. 
 
Enzymatic determination of C6 phosphorylation 
of glycogen. 
To measure the C6 phosphorylation of glycogen, 
we developed a procedure to quantitate the glucose-
6-P present in hydrolysates of glycogen or 
amylopectin.  The method is an adaptation of that 
of Zhu et al. (32).  Highly purified glycogen was 
prepared from rabbit skeletal muscle, and from wild 
type, Epm2a and Epm2b knockout mice as 
described for the determination of phosphate.  
Glycogen or amylopectin (0.5 mg) was hydrolyzed 
in 75 ml of 1N HCL for 3 hr in a boiling water bath 
followed by neutralization with 37.5 ml of 2 N 
NaOH. For all glycogen hydrolysates, 10 ml of 
sample was pipetted in triplicate into a black wall 
and clear bottom 96-well plate (Costar 3603, 
Corning).  Amylopectin samples were diluted 1:10 
and 10 ml was used. To each well, 90 ml of 
reaction mixture containing 50 mM triethanolamine 
pH 7.6, 1 mM MgCl2, 100 mM NADP+, 10 mM 
high purity resazurin (Acros Organics #18990) and 
0.2 U/ml of Clostridium Kluyveri diaphorase 
(Sigma #D2322) was added. Samples were 
centrifuged at 2,000 rpm for 30 sec. in a Fisher 
Scientific Marathon 8K centrifuge and then mixed 
at 700 rpm for 45 sec. in an Eppendorf Mixmate.  
Background fluorescence was measured from the 
bottom on a FlexStation II plate reader (Molecular 
Devises) with excitation at 530 nm and emission at 
590 nm. Then, 0.1 U/ml of Leuconostoc 
mesenteroides glucose-6-P dehydrogenase (Roche 
#10165875001) was added to each well followed 
by centrifugation, mixing, 30 min incubation at 
room temperature in the dark and determination of 
fluorescence, also measured from the bottom.  
Background fluorescence was subtracted from all 
sample readings.  Each assay included standards of 
0, 3.12, 6.25, 12.5, 25, 50, 100 and 150 pmol 
glucose-6-P which were processed in parallel with 
the samples (Fig 1A) and which demonstrate the 
linearity of the assay over this concentration range.  
Glycogen was also quantitated, as described above, 
by measuring glucose in the hydrolysates so that 
glucose-6-P could be directly related to the glucose 
content of the same sample.  
 
Since C6 phosphorylation of glycogen is rare, it 
was important to establish that the relatively high 
concentrations of glucose generated by the 
hydrolysis of glycogen or starch did not interfere 
with the detection of glucose-6-P.  Therefore, an 
assay was performed in the presence of increasing 
amounts of glucose, up to 50 nmol/assay, with or 
without a fixed amount of glucose-6-P (12.5 
pmol/assay).  As shown in Fig. 1B, glucose by 
itself, even at the highest concentration, did not 
yield significant fluorescence, indicating that the 
glucose-6-P dehydrogenase used had undetectable 
glucose dehydrogenase activity.  Most importantly, 
glucose did not interfere with the measurement of 
glucose-6-P, even when present at a 4,000-fold 
molar excess. 
 
Purification of phospho-oligosaccharides.   
Phospho-oligosaccharides from glycogen and 
amylopectin were purified essentially as described 
previously (26).  Approximately 250 mg rabbit 
skeletal muscle glycogen, purified by either the 
TCA or KOH method, or potato amylopectin were 
digested overnight at 40oC in 3 ml of 10 mM 
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sodium acetate pH 4.8 containing 1 mM CaCl2, 0.3 
mg/ml α-amylase (Bacillus sp.; Sigma-Aldrich) and 
0.3 mg/ml amyloglucosidase (Aspergillus niger; 
Sigma-Aldrich). For amylopectin digestion, 1.25% 
(v/v) DMSO was also included.  After digestion, 
samples were centrifuged at 10,000 x g for 5 min to 
remove insoluble material, the supernatants 
transferred to 2 ml screw cap tubes and heated for 5 
min in a boiling water bath followed by cooling on 
ice and further centrifugation for 10 min at 15,000 
x g at 4oC.  The individual supernatants were added 
to 2 ml (bed volume) DEAE Sepharose that had 
been extensively washed with H2O and equilibrated 
with 10 mM sodium acetate pH 4.8. The slurry was 
then placed on a nutator at 4oC overnight. The 
DEAE Sepharose resin was transferred to a 3 ml 
column, washed with 40 ml of H2O, and the flow 
rate was adjusted to 0.5 min.  Phosphorylated 
species were eluted stepwise with 4 ml each of 10 
mM, 50 mM, 100 mM, 500 mM and 1 M of 
NH4HCO3 and 1ml fractions were collected. From 
each fraction, 25-30 µl were transferred to 10 X 75 
mm borosilicate tubes in triplicate, one as a non-
hydrolyzed control for free phosphate and two for 
hydrolysis, and were dried in a Speed Vac for 
phosphate determination, as described above. The 
remainder of the fractions containing phosphate 
were dried in a Speed Vac, redissolved in water at a 
final concentration of 1 mM of phosphate and 
combined for NMR and HPAEC analyses.  The 
total recovery of phosphate from DEAE 
chromatography was ~70%. 
 
HPAEC Analysis of phospho-oligosaccharides.  
Phosphorylated oligosaccharides from rabbit 
skeletal muscle glycogen and amylopectin, 2.5 
nmol each based on phosphate concentration, were 
analyzed by high performance anionic 
chromatography (HPAEC) using a Dionex ICS3000 
with a PA200 column and detected by pulse 
amperometric detection.  All samples were filtered 
through a spin filter prior to loading into a 25 µl 
injection loop. Eluent A consisted of 100 mM 
NaOH and eluent B consisted of 100 mM NaOH 
and 1 M sodium acetate.  Phospho-oligosaccharides 
and standards were eluted from the PA200 column 
using a continuous gradient of eluent B from 0-50% 
over 60 min at a flow rate of 0.35 mln. Polyglucose 
standards from glucose (G1) up to maltooctaose 
(G8), 0.25 nmol each, were also analyzed. 
 
Analysis of phospho-oligosaccharides by NMR 
and mass spectrometry. 
 
Mass spectrometry.  MS analysis of glycogen 
phospho-oligosaccharides was performed as 
described previously (26). Briefly, 1µL of each 
sample, 1 mM with respect to phosphate, was 
mixed with the same volume of matrix solution 
containing THAP (2, 4, 6-trihydroxyacetophenone) 
and spotted on to a MALDI plate. The analysis was 
performed in reflector negative ion mode.  All 
spectra were obtained by using a Microflex LRF 
(Bruker). 
 
NMR spectroscopy. Phospho-oligosaccharides 
from glycogen and from amylopectin were 
lyophilized and deuterium-exchanged by 
lyophilization from D2O (99.9% D, Aldrich), 
dissolved in D2O (99.96% D, Cambridge Isotope), 
and transferred to a 5-mm NMR tube with magnetic 
susceptibility plugs matched to D2O (Shigemi). 
Proton-proton (gCOSY, zTOCSY, ROESY) and 
proton-carbon (gHSQC) correlated spectra were 
acquired on a Varian Inova 600 MHz spectrometer 
equipped with a 5-mm cryoprobe, and proton-
phosphorus correlated spectra were acquired on a 
Varian Inova 500 MHz spectrometer, equipped 
with an 8 mm XH room-temperature probe. All 
spectra were taken at 25 °C. Proton chemical shifts 
were referenced to internal acetone (δ = 2.218 ppm) 
(33). Carbon and phosphorus chemical shifts were 
referenced using the absolute chemical shift scale 
with Ξ values of 0.25144953 (13C) and 0.40480742 
(31P) in MNova. All experiments except the 1H-31P 
correlated spectra were acquired with standard 
Varian pulse sequences. For 1H-31P correlated 
experiments, the regular HMQC and HMQC-
TOCSY experiments were modified for 31P in the X 
channel, with a π pulse of 13.5 µs at a level of 60 
dB, and a 3JH-P coupling constant of 7 Hz. The 
spectral width was 2000 Hz in f2 and 8000 Hz in 
f1. 24 increments were acquired with 512 transients 
each. Acquisition time was 300 ms, and the mixing 
time in the 1H-31P-HMQC-TOCSY experiment was 
60 ms. The gCOSY experiment was acquired in 8 
transients and 400 increments, with an acquisition 
time of 150 ms. The zTOCSY experiment was 
acquired in 16 transients and 128 increments, with 
an acquisition time of 150 ms and a mixing time of 
80 ms. The ROESY experiment was acquired in 16 
transients and 128 increments, with an acquisition 
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time of 150 ms and a mixing time of 200 ms. For 
the 1H-13C-gHSQCad experiment, the spectral 
width was 3378 Hz in f2 and 10555 Hz in f1. 64 
increments were acquired with 200 transients each. 
The acquisition time was 150 ms, and the 1-bond 
C-H coupling constant was set to 140 Hz. The 
sample was 280 mL of a solution 2 mM with 
respect to phosphate. The raw data were processed 
in MNova using a 7-Hz Gaussian function in f2 and 
a 90°-sine2 function in f1 (1H-31P-spectra), and 7- 
and 80-Hz Gaussian functions in f2 and f1 (1H-13C 
spectra), respectively, as well as linear prediction in 
f1. 
 
RESULTS 
 
Rabbit muscle glycogen phosphorylation 
 
We previously analyzed the phosphorylation of 
rabbit skeletal muscle glycogen purified by a 
relatively mild procedure in which the most 
extreme treatment is exposure to 10% TCA at 4oC 
(26).  However, glycogen is commonly extracted 
from tissue using much harsher conditions, such as 
boiling with KOH to digest protein and other 
cellular components before precipitating glycogen 
with ethanol.  We were interested to test whether 
such extreme treatment affected the distribution of 
the phosphate within glucose residues.  Phosphate 
(34) and other ester (35) migrations are well-
established phenomena in the chemistry of sugar 
esters.  Phosphate migration under acidic conditions 
has been described most often although it has also 
been observed at high pH (36).  Therefore, 
phospho-oligosaccharides were generated from 
rabbit muscle glycogen, isolated by the "TCA" or 
the "KOH" methods, by exposure to α-amylase and 
amyloglucosidase and separated from neutral 
sugars by anion exchange chromatography (for 
details, see under "Experimental Procedures").  
Amylopectin from potato was processed similarly 
as a known source of C6 phosphorylation (37-39).  
Analysis of the phospho-glucans by HPAEC-PAD 
(Fig. 2B,C) gave a similar complex pattern to what 
we had observed previously (26), whether the 
"TCA" or "KOH" method had been used to purify 
the glycogen.  The amylopectin phospho-
oligosaccharides presented a distinct and much 
simpler elution profile (Fig. 2D).  Analysis of the 
glycogen oligosaccharides by mass spectrometry 
gave spectra that were dominated by signals 
corresponding to masses of one phosphate plus n 
hexoses, up to about n=12 (Fig. 3).  Therefore, 
although the mixture was complex as judged by 
HPAEC and mass spectrometry, the constituents 
were of similar chemical form, namely glucose 
polymers of different lengths and likely different 
branching structures, and were amenable to analysis 
by NMR. 
 
Phospho-oligosaccharides from glycogen and from 
amylopectin were thus analyzed by 2-D 
homonuclear 1H NMR (COSY, TOCSY, and 
ROESY), heteronuclear 1H-13C NMR (HSQC), and 
heteronuclear 1H-31P NMR (HMQC and HMQC-
TOCSY). The analysis produced a chemical shift 
assignment of the residues found in these 
oligosaccharide mixtures (Table 1). Most of the 
residues were present in both phospho-
oligosaccharides from glycogen and from 
amylopectin. However, differences in the 
phosphorylation pattern were detected. The 
glycogen sample showed the presence of C2, C3 
and C6 phosphomonoesters whereas amylopectin 
oligosaccharides had signals only for C3 and C6 
phosphate (Fig. 4). Panels A and D in Figure 4 
show the 1H-13C HSQC spectra of glycogen and 
amylopectin phospho-oligosaccharides, 
respectively. For comparison, we circled the areas 
in both spectra where the signals coming from C/H 
pairs of phosphorylated positions could be found in 
the glycogen spectrum. Two different Glc-6-P 
residues were present in both samples, one terminal 
(Residue e), i.e. from the non-reducing end, and 
one 4-linked (Residue f), i.e. from inside the 
oligosaccharide chain. The Glc-6-P residues gave 
minor signals in the spectrum of glycogen phospho-
oligosaccharides, but were the predominant signals 
in that of amylopectin phospho-oligosaccharides. 
Glc-3-P (Residue g) was present in both spectra, 
and Glc-2-P (Residue a) could only be detected in 
the spectrum of glycogen phospho-
oligosaccharides. To ascertain that these residues 
were indeed phosphorylated, we acquired 1H-31P 
HMQC (Fig. 4C and F) and HMQC-TOCSY (Fig. 
4B and E) spectra of both samples. The 1H-31P 
HMQC spectra, which show only peaks of protons 
that are at most 3 bonds distant from phosphorus 
atoms, confirmed the previous assignment and 
provided the 31P-chemical shift of the different 
phosphate groups. The spectrum of amylopectin 
phospho-oligosaccharides (Fig. 4F) was dominated 
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by the two Glc-6-P signals of Residues e and f with 
only a small contribution from Glc-3-P and no 
detectable Glc-2-P. Conversely, the glycogen 
phospho-oligosaccharide spectrum (Fig. 4C), 
showed strong Glc-2-P (Residue a) and Glc-3-P 
(Residue g) signals and only small peaks from 
Glc6-P (Residues e and f). The 1H-31P HMQC-
TOCSY spectra were acquired in order to provide a 
reliable assignment of the signals found in the 1H-
31P HMQC spectra. The HMQC-TOCSY 
experiments (Fig. 4B and E) showed protons that 
were up to 4 bonds distant from phosphorus atoms. 
Accordingly, Glc-2-P (Residue a) gave cross peaks 
between 31P and H-1 and H-2, Glc-3-P (Residue g) 
showed correlations between 31P and H-2, H-3, and 
H-4, and Glc-6-P showed correlations between 31P 
and H-5 and H-6. All these assignments were in 
agreement with those derived from the COSY, 
TOCSY, and 1H-13C-HSQC spectra (see Table 1). 
Quantitation of the NMR signals for the glycogen 
oligosaccharides (Table 2) revealed an 
approximately equal proportion of C2, C3 and C6 
phosphate except in the previous "TCA" sample 
(26) where the C6 phosphate was lower.  Thus, use 
of KOH treatment to prepare glycogen appeared not 
to influence the phosphate distribution as measured 
by NMR. In amylopectin, C6 phosphate was 
dominant, around 85% of the total, as would be 
expected from previous reports. 
 
Determination of C6 phosphorylation in mouse 
and rabbit muscle glycogen.  
 
Although NMR is a powerful means to demonstrate 
phosphorylation of specific glucose carbons in 
oligosaccharides, it requires significant amounts of 
material and has limitations with regard to 
quantitation.  Therefore, we developed a sensitive 
enzymatic fluorescence-based assay for glucose-6-
P in hydrolysates of purified glycogen samples.  
The method is a modification of the protocol of Zhu 
et al. (32) as described under "Experimental 
Procedures".  Coupled with the measurement of 
total phosphate present in glycogen, we are able to 
quantitate the proportion of C6 phosphorylation in 
relatively small samples of glycogen such as can be 
obtained from the muscle of individual mice.  As 
has been observed previously (24,25), the total 
phosphate content of mouse muscle glycogen, as 
measured by a Malachite green protocol (24,31), is 
significantly lower than that of rabbit muscle 
glycogen (Fig. 5; Table 3); note that phosphate is 
undetectable unless the polysaccharide is 
hydrolyzed indicating the lack of inorganic 
phosphate contamination.  Mouse and rabbit 
skeletal muscle glycogen contained similar 
proportions of C6 phosphate, around 20% (Fig. 5).  
For rabbit glycogen, this is in reasonable agreement 
with the values obtained from NMR (Table 2).  In 
absolute terms, the levels of glucose-6-P detected 
were similar to what was reported by Nitschke et al. 
(27).  Analysis of potato amylopectin indicated that 
C6 phosphate is, as expected, the predominant 
phosphomonoester, at ~75% of the total, again in 
reasonable agreement with the value from NMR.   
 
C6 phosphorylation of glycogen from laforin 
and malin knockout mice 
 
Several reports have documented that total 
glycogen phosphorylation is elevated in mouse 
models of Lafora disease (18,24) and increases with 
the age of the mice (25).  It was therefore of interest 
to assess whether increases in C6 or in C2/C3 
phosphate contributed more to the increased 
glycogen phosphate seen in laforin and malin 
knockout mice.  In the present study, the mice 
analyzed were 9-10 months old and exhibited 4.3- 
and 7.5-fold increases in total muscle glycogen 
phosphate over wild type controls in malin and 
laforin knockout animals respectively (Fig. 5; Table 
3).  The lesser elevation of glycogen 
phosphorylation in malin knockout animals as 
compared to laforin knockouts is consistent with 
other studies (18). The absolute levels of glycogen 
C6 phosphate were also increased in the knockout 
mice, but in strict proportion, ~20%, to the total 
phosphate.  Therefore, we are unable to distinguish 
whether C6 or C2/C3 phosphate correlates more 
closely with loss of laforin or malin function.  
 
DISCUSSION 
 
An important outcome from the present study is the 
confirmation of the presence of C6 phosphate in 
glycogen from rabbit and mouse skeletal muscle.  
In our previous study (26), the first to address the 
disposition of the phosphate in glycogen since the 
1990s, we had reported the presence of C2 and C3 
phosphomonoesters in rabbit muscle glycogen but 
failed to recognize the C6 phosphate.  Re-
evaluation of our earlier NMR data, analyses of 
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new samples, comparison with oligosaccharides 
derived from amylopectin as a positive control and 
direct analysis of glucose-6-P in hydrolysates of 
glycogen have enabled us to conclude that C6 
phosphate is indeed present in glycogen, consistent 
with the recent report (27). 
 
The locations of phosphate esters in glycogen has 
obvious relevance to understanding the mechanisms 
of glycogen phosphorylation.  Tagliabracci et al. 
(26) proposed that C2 phosphate might arise from 
the action of the synthetic enzyme, glycogen 
synthase, via the formation of a glucose-1,2-cyclic 
phosphodiester intermediate, the 'fast ester' of 
Leloir (40), in the active site of the enzyme and its 
subsequent transfer to the growing polyglucose 
chain.  This mechanism has been challenged (27) 
but it is supported by other independent 
experiments.  Glycogen synthase can catalyze the 
formation of the fast ester from UDP-glucose in 
vitro (41) and, by X-ray crystallography, the active 
site of glycogen synthase can accommodate fast 
ester and its cognate reaction product UMP (41).  A 
similar pathway might account for phosphorylation 
at C3 but there is no supporting evidence (26).  
However, it is hard to envisage an analogous 
mechanism for the introduction of C6 phosphate 
and future investigations of glycogen 
phosphorylation will have to address the 
mechanism for introduction of the C6 phosphate. 
 
The abnormal glycogen present in Lafora bodies is 
characterized both by increased glycogen 
phosphorylation and reduced branching frequency.  
From comparison of muscle glycogen in young and 
old laforin knockout mice, it was evident that 
elevation of phosphate preceded the alterations in 
branching structure (25) but the mechanistic 
relationship between phosphorylation and 
branching remains one of the major outstanding 
questions regarding the formation of Lafora bodies.  
It is easy to envisage how phosphorylation of a 
glucose residue in glycogen could locally affect the 
action of the branching enzyme, in the case of C6 
phosphorylation actually blocking chemically the 
ability to form an α-1,6-glycosidic linkage.  
Nitschke et al. (27) proposed that C6 
phosphorylation might in some way affect 
branching.  If so, we think that it is unlikely to be at 
a local structural level by chemically blocking a 
branch point.  If one considers a full-sized glycogen 
molecule of 55,000 glucose residues, on the model 
described in the Introduction there would be ~4000 
branch points.  Using the phosphorylation values of 
the present study, there would be on average three 
to four C6 phosphates per molecule and seventeen 
C2/C3 phosphates in normal glycogen.  C6 
phosphorylation could therefore block no more than 
0.1% of the potential branch points.  Even in 
hyperphosphorylated glycogen from laforin or 
malin knockout mice, this value increases no more 
than ten-fold.  We favor the idea that glucose 
phosphorylation has wider ranging effects on 
overall glycogen structure (1,25) by disrupting the 
complex hydrogen bonding and other interactions 
that stabilize polyglucose helices (42).  This idea 
has been extensively discussed in relation to 
amylopectin, where phosphorylation functions to 
disrupt the organized structure of semi-crystalline 
regions of the polysaccharide as part of the 
degradative process (37,39,43,44).  C3 phosphates 
induce strain in the helix and C6 phosphate, while 
more tolerated, can affect helix packing (43).  In 
this way, the gross changes in Lafora glycogen 
physical chemical properties can be explained but 
the exact mechanism by which branching is 
impaired still needs to be worked out. 
 
In their recent study, Nitschke et al. (27) portrayed 
C6 phosphorylation of glycogen as being especially 
important for Lafora body formation.  However, 
they did not measure total glycogen phosphate 
content so that the proportion of C6 phosphate was 
not determined.  With our protocol, we were able to 
establish that C6 phosphorylation represents ~20% 
of the total phosphate.  This proportion was 
unchanged as the total glycogen phosphorylation 
increased 4- to 8-fold in malin and laforin knockout 
mice respectively.  Thus, the relative importance of 
C6 phosphorylation as compared to C2 or C3 
phosphorylation in promoting the aberrant glycogen 
structure associated with the formation of Lafora 
bodies in mouse models of Lafora disease is, in our 
opinion, an open question.   
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LEGENDS TO FIGURES 
 
Figure 1.  Assay of glucose-6-P.  A. Standard curve for the measurement of glucose-6-P using the assay 
described under " Experimental Procedures".  B.  Analysis of a fixed amount of glucose-6-P (12.5 
pmol/assay) in the presence of 0 - 50 nmol/assay of glucose, mimicking the background of free glucose 
that could result from the hydrolysis of glycogen or starch. 
 
Figure 2.  Analysis of phospho-oligosaccharides purified from glycogen and amylopectin by 
HPAEC.  Oligosaccharides were separated by HPAEC with PAD using a PA200 column as detailed 
under " Experimental Procedures".  For phospho-oligosaccharides, 2.5 nmol based on phosphate content 
were analyzed.  A. Polyglucose standards (0.25 nmol) from glucose (G1) up to maltooctaose (G8).  B. 
Phospho-oligosaccharides purified from rabbit muscle glycogen prepared by the "TCA" protocol.  C.  
Phospho-oligosaccharides purified from rabbit muscle glycogen prepared by the "KOH" protocol.  D.  
Phospho-oligosaccharides purified from amylopectin. 
 
Figure 3.  Analysis of phospho-oligosaccharides purified from glycogen by MALDI-TOF mass 
spectrometry.  A 1-µL aliquot of phospho-oligosaccharide solution (1 mM in phosphate ester), prepared 
by the “TCA” (A) or KOH” (B) protocol, was analyzed using THAP matrix in negative ion mode. 
MALDI spectra are shown in which a series of glycogen phosphate peaks from both preparations was 
detected. The main signals observed are series of glucose oligomers with one mole of phosphate, starting 
with 3 hexose units. 
 
Figure 4. Analysis of phospho-oligosaccharides purified from glycogen and amylopectin by NMR. 
Two-dimensional heteronuclear NMR spectra were acquired as described in “Experimental Procedures” 
with D2O as solvent from samples 2 mM with respect to phosphate. A. 1H-13C-gHSQC spectrum of 
purified glycogen phospho-oligosaccharides, prepared by the “KOH” protocol. The signals from H/C 
pairs of phosphorylated positions are circled and labeled. The contribution of each isomer was estimated 
by measuring the peak volumes of the labeled signals; B. 1H-31P-HMQC-TOCSY spectrum of purified 
glycogen phospho-oligosaccharides, showing phosphorus correlations to H-1 and H-2 of Glc-2-P and to 
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H-2, H-3, and H-4 of Glc-3-P; C. 1H-31P-HMQC spectrum of purified glycogen phospho-
oligosaccharides, showing phosphorus correlations to H-2 of Glc-2-P, H-3 of Glc-3-P, and H-6 of Glc-6-
P;  D. gHSQC spectrum of purified amylopectin phospho-oligosaccharides. The same areas as in Panel A 
are circled although no C2 phosphate was detected in amylopectin. The contribution of each isomer was 
estimated by measuring the peak volumes of the labeled signals; E. 1H-31P-HMQC-TOCSY spectrum of 
purified amylopectin phospho-oligosaccharides, showing phosphorus correlations to H-5 and H-6 of 4-
Glc-6-P, to H-4, H-5, and H-6 of t-Glc-6-P, and to H-2, H-3, and H-4 of Glc-3-P; F. 1H-31P-HMQC 
spectrum of purified glycogen phospho-oligosaccharides, showing phosphorus correlations to H-3 of Glc-
3-P and H-6 of Glc-6-P. The lines connecting the signals are coded to the different phosphorylated 
glucose residues; e and f: solid, g: dashed, a: dash-dot lines. 
 
Figure 5.  Total phosphate and C6 phosphate content of rabbit and mouse glycogen and 
amylopectin.   The total inorganic phosphate (open bars) and glucose-6-P (filled bars) in hydrolysates of 
glycogen or amylopectin were measured as described under " Experimental Procedures".  Shown are 
analyses of glycogen purified from wild type (4), Epm2b-/- (5) and Epm2a-/- (4) mouse muscle, where 
the numbers in parentheses denote the number of animals analyzed.  For rabbit muscle glycogen (5-11) 
and potato amylopectin (4), the number of replicate analyses is indicated.  The percentage of C6 
phosphorylation is shown above the filled bars.  The error bars indicate the standard error of the mean; 
asterisks denote p ≤ 0.01 with respect to wild type mouse glycogen phosphate. 
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TABLES 
 
Table 1. Proton, carbon, and phosphorus chemical shifts (in ppm) of phosphorylated 
amylopectin and glycogen oligosaccharides 
 
 Residue  1 2 3 4 5 6 
a1 t-α-Glc-2-P-(1→) 1H 5.67 3.98 3.76 3.49 3.70 3.83/3.77 
  13C 100.0 77.3 74.7 71.8 75.3 63.3 
  31P  1.12     
b t-α-Glc-(1→4) 1H 5.60 3.57 3.66 3.43 3.66 3.83/3.77 
  13C 101.1 74.0 75.4 72.1 75.4 63.3 
c2 t-α-Glc-(1→4-Glc-6-P) 1H 5.48 3.56 3.70 3.35 n.d.3 3.92/3.80 
  13C 101.6 74.1 75.4 72.4 n.d. 63.5 
d 4-α-Glc-(1→4) 1H 5.39 3.59 3.97 3.64 3.84 3.83/3.77 
  13C 102.2 74.1 76.0 79.7 73.8 63.3 
e t-α-Glc-6-P 1H 5.38 3.61 3.68 3.51 3.81 4.05/4.05 
  13C 102.4 74.1 75.4 71.5 74.5 66.2 
  31P      2.07 
f 4-α-Glc-6-P 1H 5.37 3.63 n.d. 3.71 3.98 4.12/4.03 
  13C 102.2 74.1 n.d. 78.1 73.0 66.6 
  31P      1.02 
g 4-α-Glc-3-P 1H 5.35 3.75 4.46 3.81 3.87 n.d. 
  13C 102.4 74.6 79.9 76.4 73.8 n.d. 
  31P   2.81    
h 4-α-Glcred 1H 5.21 3.56 3.95 3.64 n.d. n.d. 
  13C 94.5 74.0 76.0 79.7 n.d. n.d. 
i 4-β-Glcred 1H 4.64 3.27 3.75 3.64 n.d. n.d. 
  13C 98.5 76.6 78.8 79.7 n.d. n.d. 
j1 4,6-α-Glcred 1H 5.22 3.55 3.96 3.64 3.93 3.98/3.83 
  13C 94.6 74.2 76.0 79.7 72.7 69.7 
k1 t-α-Glc-(1→6) 1H 4.99 3.54 3.74 3.44 3.86 n.d. 
  13C 101.5 74.7 74.2 72.1 73.8 n.d. 
l1 4-α-Glc-(1→6) 1H 4.95 3.59 4.01 3.63 3.85 n.d. 
  13C 100.7 74.1 73.0 80.6 74.0 n.d. 
m1 4,6-β-Glcred 1H 4.65 3.25 3.77 3.62 3.60 3.97/3.73 
  13C 98.5 76.7 78.9 80.6 77.3 68.8 
1only observed in glycogen phospho-oligosaccharides 
2only observed in amylopectin phospho-oligosaccharides 
3n.d.=not determined 
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Table 2.  Phosphomonester distribution in phospho-oligosaccharides from glycogen and 
amylopectin based on NMR analyses. 
 
Sample C2 phosphate (%) C3 phosphate (%) C6 phosphate (%) 
Glycogen 
  TCA (2010) 
  TCA (2013) 
  KOH 
 
28 
30 
29 
 
53 
39 
37 
 
19 
31 
34 
Amylopectin 0 13 87 
 
The relative proportions of C2, C3 and C6 phosphorylation were estimated by integrating the 
corresponding signals in NMR experiments such as shown in Fig. 4.  Samples were 
oligosaccharides prepared from the indicated source as described under "Experimental 
Procedures".  In the case of the glycogen "TCA" samples, the data refer to re-evaluation of a 
previous sample (2010; (26)) as well as a new sample analyzed in the present study.   
 
Table 3.  Determination of total phosphate and glucose-6-P in glycogen and amylopectin  
 
Sourcea Glycogen phosphate 
(mol/mol) x 10-3 
% C6 
phosphate 
Glucose residues per  Fold increase 
over WT 
 Total C6  Total P C6 P Total P C6 P 
WT (4) 0.371 ± 0.03 0.063 ± 0.007 17 2700 15800 1 1 
Epm2b-/- 
(5) 1.612 ± 0.19 0.263 ± 0.015 16 620 3800 4.3 4.0 
Epm2a-/- 
(4) 2.785 ± 0.09 0.582 ± 0.021 21 360 1720 7.5 9.2 
Rabbit  
(5-11) 1.525 ± 0.10 0.324 ± 0.001 21 650 3090 
 
NAb 
 
NA 
Amylo-
pectin (4) 4.403 ± 0.18 3.307 ± 0.034 76 227 300 
 
NA 
 
NA 
 
aFor the analyses of muscle glycogen from wild type (WT), Epm2b-/- and Epm2a-/- mice, the 
numbers in parentheses refer to the number of samples, each from a separate mouse, that were 
analyzed.  For the analyses of rabbit muscle glycogen and amylopectin, the numbers in 
parentheses refer to the number of independent, replicate analyses made from the same starting 
material. 
bNA, not applicable   
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